1. Home
  2. WDAY vs ONC Comparison

WDAY vs ONC Comparison

Compare WDAY & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Workday Inc.

WDAY

Workday Inc.

SELL

Current Price

$177.86

Market Cap

47.7B

Sector

Technology

ML Signal

SELL

Logo BeiGene Ltd. American Depositary Shares

ONC

BeiGene Ltd. American Depositary Shares

SELL

Current Price

$392.98

Market Cap

40.6B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
WDAY
ONC
Founded
2005
2010
Country
United States
Switzerland
Employees
N/A
12000
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.7B
40.6B
IPO Year
2012
2015

Fundamental Metrics

Financial Performance
Metric
WDAY
ONC
Price
$177.86
$392.98
Analyst Decision
Buy
Strong Buy
Analyst Count
42
27
Target Price
$208.96
★ $472.77
AVG Volume (30 Days)
★ 1.9M
370.1K
Earning Date
11-24-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
32.82
★ 140.43
EPS
★ 3.41
0.56
Revenue
★ $2,143,050,000.00
$238,387,000.00
Revenue This Year
$11.67
$29.61
Revenue Next Year
$10.44
$14.90
P/E Ratio
★ $50.83
$713.20
Revenue Growth
36.55
★ 22179.16
52 Week Low
$110.36
$253.95
52 Week High
$236.80
$424.73

Technical Indicators

Market Signals
Indicator
WDAY
ONC
Relative Strength Index (RSI) 31.48 55.06
Support Level $113.15 $341.67
Resistance Level $198.38 $424.73
Average True Range (ATR) 6.89 9.78
MACD -2.70 -0.10
Stochastic Oscillator 1.91 67.14

Price Performance

Historical Comparison
WDAY
ONC

About WDAY Workday Inc.

Workday is a software company that offers human capital management, financial management, and business planning solutions for enterprises. Known for being a cloud-only software provider, Workday was founded in 2005 and is headquartered in Pleasanton, California.

About ONC BeiGene Ltd. American Depositary Shares

Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.

Share on Social Networks: